Proactive Investors - Run By Investors For Investors

Futura Medical Plc progresses condom and pain relief products

Health group expects to have more of a commercial focus in 2016
Futura Medical Plc progresses condom and pain relief products
Futura said 2015 was a period of intense clinical activity

Futura Medical Plc (LON:FUM) forecast lower research & development spending this year as it reported progress with its pain relief and sexual health products.

Futura said 2015 was a period of intense clinical activity during which it made "significant advances" in programmes in erectile dysfunction and pain relief.

It said it expected R&D outlay to be significantly lower this year, when it would have more of a focus on commercial product development.

In June, the group began a pivotal efficacy study for its MED2002 treatment for erectile dysfunction, which is expected to produce headline results by the end of the first half.

Futura has achieved an extended shelf life for its CSD500 condom, which maintains a firmer erection, maximises penile size and gives women a longer-lasting sexual experience.

It has applied to get a modified manufacturing process for the condom approved in Europe and expects to receive consent in the middle of this year.

It also reported major progress in its pain relief portfolio during 2015, specifically in achieving statistically significant results in a study of two gels, TPR100 and TIB200.

"The US also represents a very significant opportunity for TPR100 and we are preparing for a meeting with the US Food and Drug Administration in the near future to clarify the remaining requirements for US regulatory approval," the group said in its results for the year to the end of December.

Net losses widened to £5.08mln from £3mln in 2014, reflecting two clinical studies undertaken in 2015.

Chief executive James Barder said: "We have made important progress with the shelf life extension of our novel condom CSD500 and we look forward to the start of licensee launches in 2016 and beyond.

"Futura has also made significant advances in its clinical programmes in erectile dysfunction and pain relief. In 2016 we expect to build on that progress and look forward to providing further updates."
















Why Invest In Futura Medical plc.? Read More Here

Register here to be notified of future FUM Company articles
View full FUM profile

Futura Medical plc. Timeline

Related Articles

September 09 2015
The impending return of ImmuCyst, a bladder cancer treatment, following a three year absence is one of the drivers as is a new product, Diclectin.
March 15 2016
Pain relief and sexual health group makes progress with flagship products
January 25 2016
Broker N+1 Singer said: “The licensing agreement with a large US biotech is excellent news and illustrates the commercial potential of Abzena’s ThioBridge platform for the design of better antibody-drug conjugate drugs.”

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.